ERBB2 and esophageal adenocarcinoma: Another phase 3 CheckMate-649 trial (NCT#02872116), which enrolled 1581 patients with untreated, unresectable, Human Epidermal Growth Factor Receptor 2 (HER2)-negative G/GEJ, or esophageal adenocarcinoma, demonstrated the acceptable safety profile and efficacy of nivolumab as a first-line treatment [7,18].